Listen to the full audio podcast episode:
Watch other videos from this interview:
Rebekah Martin, senior VP of reward, inclusion, and talent acquisition at AstraZeneca, discusses ways to address the need for talent in pharma, how pharma can increase more interest in young talent, and how many roles in pharma will require a degree in the coming years in this Pharmaceutical Executive Podcast video.
Across most industries, finding and keeping the right talent is a constant challenge for companies. This challenge is perhaps even more prevalent in the pharmaceutical industry, which requires a significant amount of specialization.
Rebekah Martin, senior VP of reward, inclusion, and talent acquisition for AstraZeneca, discusses recruiting talent in pharma with Meg Rivers, managing editor. Specifically, Martin talks about:
Listen to the full audio podcast episode:
Watch other videos from this interview:
Rebekah Martin is the senior vice president of reward, inclusion, and talent acquisition for AstraZeneca. Martin has a master’s degree in molecular and cellular biochemistry from the University of Oxford and went on to qualify as a lawyer in the UK, joining AstraZeneca in 2011. Since joining, she has held a number of progressively senior roles in the legal team based in the UK and Singapore. She moved to her current role in the HR team in April 2018, where she leads the team responsible for reward strategy, design, and governance at AstraZeneca, talent acquisition, and leads the implementation of AstraZeneca’s global inclusion and diversity strategy. Martin is passionate about breaking down the stigma that can be associated with neurodiversity and believes there is a strong connection between diversity of thought, innovation, and performance.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.